New drug aims to tame severe viral lung infections

NCT ID NCT07633288

Recruiting now Disease control Sponsor: SynAct Pharma Aps Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether a daily pill called AP1189 can help hospitalized patients with breathing failure due to viruses like flu, RSV, or COVID-19. About 96 adults will receive either AP1189 or a placebo for 14 days, on top of usual care. The main goal is to see if the drug reduces serious outcomes like death, need for a breathing machine, or kidney failure within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AP1189 (a melanocortin agonist pill)
What this could lead to: If it works, this could point toward a new add-on treatment to reduce severe complications from respiratory viral infections like flu, RSV, or COVID-19.
What could go wrong: This is an early Phase 2 proof-of-concept trial with only 96 participants, so results may not apply broadly. The drug is tested on top of standard care, and its benefit over placebo is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY VIRAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY VIRAL INFECTION

Contacts and locations

Locations

Aotearoa Clinical Trial Trust, Esme Green Building, Middlemore Hospital
RECRUITING

Auckland, 2025, New Zealand
Christchurch Hospital, 2 Riccarton Avenue,
NOT_YET_RECRUITING

Christchurch, 8011, New Zealand
Clinical Center of Montenegro, Clinic for Infectious Diseases
RECRUITING

Podgorica, Podgorica Municipality, 81000, Montenegro
Health Center Uzice, General Hospital Uzice
RECRUITING

Užice, Zlatibor District, 31000, Serbia
MRINZ, 7 CSB Building, Wellington Hospital
RECRUITING

Wellington, 6021, New Zealand
Te Toka Tumai Auckland, Auckland City Hospital
RECRUITING

Auckland, 1023, New Zealand
University Clinical Center Republic of Srpska, Clinic for Infectious Diseases
RECRUITING

Banja Luka, Republika Srpska, 78000, Bosnia and Herzegovina
University Clinical Centre Nis, Clinic for Infectious Diseases
RECRUITING

Niš, Nišava District, 18000, Serbia
University Clinical Centre Sarajevo, Clinic for Infectious Diseases
RECRUITING

Sarajevo, Sarajevo Canton, 71000, Bosnia and Herzegovina
University Clinical Centre of Serbia, Clinic for Infectious Diseases
RECRUITING

Belgrade, 11000, Serbia
University Clinical Hospital Mostar, Clinic for Infectious Diseases
RECRUITING

Mostar, Herzegovina-Neretva Canton, 88000, Bosnia and Herzegovina

More trials for these conditions

Other studies related to the condition(s) this trial covers.